Page 138 - 《中国药房》2022年12期

[49] KONSTANTINOPOULOS P A，WILSON A J，SASKOWSKI nation repair in ovarian cancer cells to confer increased
J，et al. Suberoylanilide hydroxamic acid（SAHA）enhances sensitivity to PARP inhibition[J]. Cell Death Dis，2017，8
olaparib activity by targeting homologous recombination （10）：e3070.
DNA repair in ovarian cancer[J]. Gynecol Oncol，2014， [55] WANG H G，ZHANG S，SONG L Y，et al. Synergistic le-
133（3）：599-606. thality between PARP-trapping and alantolactone-induced
[50] YIN L L，LIU Y H，PENG Y C，et al. PARP inhibitor veli- oxidative DNA damage in homologous recombination-pro-
parib and HDAC inhibitor SAHA synergistically co-target ficient cancer cells[J]. Oncogene，2020，39（14）：2905-
the UHRF1/BRCA1 DNA damage repair complex in pro- 2920.
state cancer cells[J]. J Exp Clin Cancer Res，2018，37（1）： [56] ZHANG N，TIAN Y N，ZHOU L N，et al. Glycogen syn-
153. thase kinase 3β inhibition synergizes with PARP inhibitors
[51] LIANG B Y，XIONG M，JI G B，et al. Synergistic suppres- through the induction of homologous recombination defi-
sive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor ciency in colorectal cancer[J]. Cell Death Dis，2021，12
SAHA on proliferation of liver cancer cells[J]. Huazhong （2）：183.
Keji Daxue Xuebao Yixue Yingdewen Ban，2015，35（4）： [57] KONDRASHOVA O，TOPP M，NESIC K，et al. Methyla-
535-540. tion of all BRCA1 copies predicts response to the PARP
[52] BALDAN F ，MIO C ，ALLEGRI L ，et al. Synergy inhibitor rucaparib in ovarian carcinoma[J]. Nat Commun，
between HDAC and PARP inhibitors on proliferation of a 2018，9（1）：3970.
human anaplastic thyroid cancer-derived cell line[J]. Int J [58] NOORDERMEER S M，ADAM S，SETIAPUTRA D，
Endocrinol，2015，2015：978371. et al. The shieldin complex mediates 53BP1-dependent
[53] HEGDE M，MANTELINGU K，PANDEY M，et al. Com- DNA repair[J]. Nature，2018，560（7716）：117-121.
binatorial study of a novel poly（ADP-ribose）polymerase [59] RAY CHAUDHURI A，CALLEN E，DING X，et al. Repli-
inhibitor and an HDAC inhibitor，SAHA，in leukemic cell cation fork stability confers chemoresistance in BRCA-de-
lines[J]. Target Oncol，2016，11（5）：655-665. ficient cells[J]. Nature，2016，535（7612）：382-387.
[54] HOU D，XU G W，ZHANG C B，et al. Berberine induces （收稿日期：2021-12-09 修回日期：2022-02-15）
oxidative DNA damage and impairs homologous recombi- （编辑：曾海蓉）

（上接第1524页）
[50] YEAGER S D，OLIVER J E，SHORMAN M A，et al. Intensive Care Med，2015，41（1）：103-110.
Comparison of linezolid step-down therapy to standard [55] RAO G G，KONICKI R，CATTANEO D，et al. Therapeu-
parenteral therapy in methicillin-resistant Staphylococcus tic drug monitoring can improve linezolid dosing regi-
aureus bloodstream infections[J]. Int J Antimicrob mens in current clinical practice：a review of linezolid
Agents，2021，57（5）：106329. pharmacokinetics and pharmacodynamics[J]. Ther Drug
[51] ZHANG Y M，YU W，ZHOU N，et al. High frequency of Monit，2020，42（1）：83-92.
thrombocytopenia in patients with acute-on-chronic liver [56] KAWASUJI H，TSUJI Y，OGAMI C，et al. Proposal of ini-
failure treated with linezolid[J]. Hepatobiliary Pancreat tial and maintenance dosing regimens with linezolid for
Dis Int，2015，14（3）：287-292. renal impairment patients[J]. BMC Pharmacol Toxicol，
[52] IM J H，LEE J S，CHUNG M H，et al. Effect of a serum 2021，22（1）：13.
lactate monitoring recommendation policy on patients [57] CAZAVET J，BOUNES F V，RUIZ S，et al. Risk factor
treated with linezolid[J]. Medicine，2021，100（1）：e23790. analysis for linezolid-associated thrombocytopenia in criti-
[53] ZHAO W J，KONG L T，WU C C，et al. Prolonged infu- cally ill patients[J]. Eur J Clin Microbiol Infect Dis，2020，
sion of linezolid is associated with improved pharmacoki- 39（3）：527-538.
netic/pharmacodynamic（PK/PD）profiles in patients with [58] LUQUE S，HOPE W，SORLI L，et al. Dosage individua-
external ventricular drains[J]. Eur J Clin Pharmacol，2021， lization of linezolid：precision dosing of linezolid to opti-
77（1）：79-86. mize efficacy and minimize toxicity[J]. Antimicrob
[54] DE PASCALE G，FORTUNA S，TUMBARELLO M， Agents Chemother，2021，65（6）：e02490-e02420.
et al. Linezolid plasma and intrapulmonary concentrations （收稿日期：2022-02-11 修回日期：2022-05-23）
in critically ill obese patients with ventilator-associated （编辑：邹丽娟）
pneumonia：intermittent vs continuous administration[J].

·1536 · China Pharmacy 2022 Vol. 33 No. 12 中国药房 2022年第33卷第12期